PMV Pharmaceuticals reported third-quarter results alongside clinical and corporate updates for its cancer drug rezatapopt. The company has completed enrollment for the primary-analysis group in a pivotal Phase 2 ovarian-cancer study and plans to present data from the trial at a scientific meeting. It is targeting a first-quarter 2027 application for accelerated approval in platinum-resistant or platinum-refractory ovarian cancer with a TP53 Y220C mutation.
PMV also said a recently completed $50 million public offering extends its expected cash runway into the first quarter of 2028.
Clinical and regulatory update
- Enrollment is complete for the primary-analysis population in the ovarian-cancer portion of PYNNACLE, a Phase 2 trial of rezatapopt. PMV plans to present data from that group, along with updates on the trial’s other cohorts, in a late-breaking oral presentation at the 2026 EORTC-NCI-AACR Symposium.
- In an interim analysis based on a May 14, 2026 data cutoff, 35 of 76 patients in the efficacy population responded to treatment, an overall response rate of 46% by investigator assessment. That total included four confirmed complete responses, 29 confirmed partial responses and two unconfirmed partial responses.
- Among patients with confirmed responses, the median time to response was 1.3 months and the median duration of response was 10 months.
- PMV described rezatapopt’s safety profile as consistent across trial cohorts, with treatment-related side effects mostly mild or moderate. Five percent of patients discontinued treatment because of treatment-related side effects.
- The company plans to submit an application in the first quarter of 2027 seeking accelerated approval for rezatapopt in platinum-resistant or platinum-refractory ovarian cancer patients with the TP53 Y220C mutation. The drug has received FDA Fast Track designation for certain advanced solid tumors with that mutation and Orphan Drug designation for TP53 Y220C-positive ovarian, fallopian tube and primary peritoneal cancers.
Financing, leadership and finances
- PMV completed an oversubscribed $50 million public offering in August. The company said the financing supports its expected cash runway into the first quarter of 2028; the announcement did not provide further offering terms.
- Cash, cash equivalents and marketable securities totaled $108.5 million at September 30, 2026, compared with $112.9 million at the end of 2025. Net cash used in operations during the first nine months of 2026 was $52.4 million, down from $56.4 million in the same period a year earlier.
- PMV reported a third-quarter net loss of $34.4 million, compared with $21.1 million a year earlier. The larger loss primarily reflected a $12.8 million non-cash charge from a change in the fair value of a warrant liability and $2.3 million of offering costs allocated to that liability, both related to the August financing.
- Research and development expenses fell to $16.1 million from $18.2 million, mainly because of lower contract research costs for rezatapopt. General and administrative expenses edged down to $4.0 million from $4.3 million.
- Matt Eckler of Samsara BioCapital joined PMV’s board, and Philip Herman was appointed chief commercial officer.
What changes
The offering adds financing and extends PMV’s stated cash runway, while the company’s next major clinical milestone is the planned presentation of the completed primary-analysis group. The interim response figures reported here are based on an earlier data cutoff; PMV said it intends to provide the primary-analysis results at the upcoming symposium.